Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin and Sovodak for COVID-19
IRCT20200408046987N2Phase 3Completed
- Sponsor
- Akam Tejarat Fartak Farasoo
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivermectin and sofosbuvir + daclatasvir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Akam Tejarat Fartak Farasoo. Primary endpoints: Chest CT scan, Hospitalization time and 2 more. Started Oct 2020; status: completed.
02
Drugs
ivermectinsofosbuvir + daclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200408046987N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200408046987N2.